Published in Prostate Int on June 30, 2014
Asia prostate cancer study (A-CaP Study) launch symposium. Prostate Int (2016) 1.38
Prostate cancer trends in Asia. World J Urol (2016) 0.75
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst (2008) 6.79
The incidences and mortalities of major cancers in China, 2009. Chin J Cancer (2013) 5.17
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol (2012) 2.28
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Prediction of cancer incidence and mortality in Korea, 2012. Cancer Res Treat (2012) 1.75
REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol (2005) 1.72
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
The quantitative Gleason score improves prostate cancer risk assessment. Cancer (2012) 1.57
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer (2012) 1.38
Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int (2006) 1.36
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol (2007) 1.34
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol (2011) 1.33
Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol (2005) 1.28
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res (2009) 1.26
The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol (2011) 1.23
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol (2008) 1.18
Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol (2011) 1.09
Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol (2004) 1.07
The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. Yonsei Med J (2013) 1.03
Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center. Jpn J Clin Oncol (2012) 0.93
Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol (2006) 0.92
Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol (2010) 0.91
Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU Int (2012) 0.90
Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition). Int J Urol (2008) 0.89
Active surveillance in prostate cancer: patient selection and triggers for intervention. Curr Opin Urol (2012) 0.85
Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol. Jpn J Clin Oncol (2013) 0.84
Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. Int J Urol (2004) 0.81
The Establishment of K-CaP (the Multicenter Korean Prostate Cancer Database). Korean J Urol (2013) 0.80
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer (2009) 4.45
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer (2009) 2.64
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res (2003) 2.34
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol (2009) 2.31
Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res (2005) 2.29
A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet (2012) 2.29
Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst (2005) 2.23
Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol (2008) 2.23
Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology (2010) 2.23
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. Urology (2009) 2.23
Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. Int J Urol (2014) 2.21
Retzius-sparing robot-assisted laparoscopic radical prostatectomy: combining the best of retropubic and perineal approaches. BJU Int (2014) 2.14
Expression and functional role of β3 -adrenoceptors in the human ureter. Int J Urol (2013) 2.13
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Laparoscopic simultaneous bilateral adrenalectomy for testosterone-secreting bilateral adrenal tumors. Int J Urol (2013) 2.03
Risk factors for chronic kidney disease after chemotherapy for testicular cancer. Int J Urol (2012) 2.03
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res (2010) 1.89
Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res (2005) 1.85
Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol (2006) 1.78
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet (2012) 1.78
Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol (2012) 1.74
Laparoscopic resection of Bismuth type I and II hilar cholangiocarcinoma: an audit of 14 cases from two institutions. Dig Surg (2011) 1.71
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res (2005) 1.66
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol (2009) 1.63
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int (2013) 1.61
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int (2007) 1.61
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology (2013) 1.59
Mouse urogenital development: a practical approach. Differentiation (2003) 1.59
Prevalence of human papillomavirus infection in the urinary tract of men with urethritis. Int J Urol (2010) 1.58
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58
The quantitative Gleason score improves prostate cancer risk assessment. Cancer (2012) 1.57
Korean urologist's view of practice patterns in diagnosis and management of benign prostatic hyperplasia: a nationwide survey. Yonsei Med J (2010) 1.57
High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol (2003) 1.57
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2010) 1.57
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res (2009) 1.56
Incidentally detected inguinoscrotal bladder hernia. Korean J Urol (2011) 1.54
The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer (2014) 1.51
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer (2012) 1.50
Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. Int J Urol (2014) 1.50
Intermediate-term outcomes of robot-assisted laparoscopic nephroureterectomy in upper urinary tract urothelial carcinoma. Clin Genitourin Cancer (2013) 1.50
Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study. Urology (2012) 1.49
Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull (2006) 1.48
Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious rats. Exp Neurol (2002) 1.48
Totally tubeless versus standard percutaneous nephrolithotomy for renal stones: analysis of clinical outcomes and cost. J Endourol (2014) 1.48
Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips. Urology (2011) 1.47
Aggressive angiomyxoma in the scrotum expressing androgen and progesterone receptors. Int J Urol (2003) 1.47
Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. Asian J Androl (2011) 1.46
Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia. Urology (2010) 1.46
Does performance of robot-assisted laparoscopic radical prostatectomy within 2 weeks of prostate biopsy affect the outcome? Int J Urol (2010) 1.46
Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest (2005) 1.46
Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol (2010) 1.45
Feasibility and accuracy of computational robot-assisted partial nephrectomy planning by virtual partial nephrectomy analysis. Int J Urol (2015) 1.44
Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol (2013) 1.44
Patent processus vaginalis in adults who underwent robot-assisted laparoscopic radical prostatectomy: predictive signs of postoperative inguinal hernia in the internal inguinal floor. Int J Urol (2012) 1.44
Use of social media in urology: data from the American Urological Association (AUA). BJU Int (2014) 1.43
One-stage repair of severe hypospadias using modified tubularized transverse preputial island flap with V-incision suture. J Pediatr Urol (2008) 1.43
Ion channel TRPM8 promotes hypoxic growth of prostate cancer cells via an O2 -independent and RACK1-mediated mechanism of HIF-1α stabilization. J Pathol (2014) 1.43
Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer. Int J Urol (2015) 1.43
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet (2002) 1.43
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
Role of HCN channels in neuronal hyperexcitability after subarachnoid hemorrhage in rats. J Neurosci (2012) 1.42
Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury. Neurol Sci (2012) 1.42
Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: a meta-analysis. Int Clin Psychopharmacol (2012) 1.42
Comparison of testosterone fractions between Framingham Heart Study participants and Japanese participants. Int J Urol (2014) 1.42
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol (2012) 1.40
Proximal bulbar periurethral abscess. Int Braz J Urol (2013) 1.40
Favorable risk factors in patients with positive surgical margin after robot-assisted radical prostatectomy. Can J Urol (2014) 1.40
Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies. Int J Urol (2003) 1.40
Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report. Int J Urol (2006) 1.40
Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan. Int J Urol (2010) 1.39